UBS Group
FTH

UBS Group’s Faeth Therapeutics FTH Stock Holding History

UBS Group’s Portfolio FTH Stock Details FTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$143K Buy
+4,529
New +$90.5K ﹤0.01% 6814
2025
Q4 		– Sell
-873
Closed -$8.25K – 11105
2025
Q3 		$8.25K Sell
873
-1,267
-59% -$10.5K ﹤0.01% 8673
2025
Q2 		$18.4K Buy
2,140
+13
+0.6% +$93 ﹤0.01% 8500
2025
Q1 		$16.8K Buy
+2,127
New +$20.2K ﹤0.01% 8344
2024
Q4 		– Hold
0
– – – 9863
2024
Q2 		– Sell
-7
Closed -$146 – 10039
2024
Q1 		$146 Buy
+7
New +$121 ﹤0.01% 8781
2023
Q3 		– Sell
-326
Closed -$7.42K – 9929
2023
Q2 		$7.42K Buy
326
+154
+90% +$4.51K ﹤0.01% 7294
2023
Q1 		$5.16K Buy
172
+117
+213% +$3.47K ﹤0.01% 8077
2022
Q4 		$1.64K Sell
55
-601
-92% -$17.7K ﹤0.01% 9826
2022
Q3 		$20K Sell
656
-17
-3% -$668 ﹤0.01% 7407
2022
Q2 		$31K Sell
673
-8
-1% -$300 ﹤0.01% 6366
2022
Q1 		$31K Sell
681
-439
-39% -$34.9K ﹤0.01% 6967
2021
Q4 		$130K Buy
1,120
+1,070
+2,140% +$160K ﹤0.01% 6054
2021
Q3 		$11K Buy
50
+15
+43% +$2.73K ﹤0.01% 7905
2021
Q2 		$7K Sell
35
-70
-67% -$17.3K ﹤0.01% 8351
2021
Q1 		$31K Buy
+105
New +$35.1K ﹤0.01% 6990

Other funds holding FTH

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

UBS Group's FTH Position: Q1 2026 in Review

UBS Group opened a new position in Faeth Therapeutics (FTH) in Q1 2026: 4,529 shares worth $143K. The stake represents ﹤0.01% of the portfolio and ranks #6814 among its holdings. This is a return to the name: UBS Group previously reported a position in FTH as recently as Q3 2025.

UBS Group first reported a position in FTH in Q1 2021 and has held it in 15 quarters since. 30 funds tracked by Wall St. Rank hold FTH as of Q1 2026.

  • UBS Group held 4,529 shares of Faeth Therapeutics worth $143K as of Q1 2026.
  • Faeth Therapeutics was a new UBS Group position in Q1 2026.
  • Faeth Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #6814 holding.
  • UBS Group first reported a position in Faeth Therapeutics in Q1 2021 and has held it in 15 quarters since.
  • 30 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.